Syros Pharmaceuticals, Inc. Stock price

Equities

SYRS

US87184Q2066

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
5.84 USD -6.56% Intraday chart for Syros Pharmaceuticals, Inc. -7.74% -25.03%
Sales 2024 * 6.33M Sales 2025 * 82.42M Capitalization 152M
Net income 2024 * -122M Net income 2025 * -112M EV / Sales 2024 * 14.8 x
Net cash position 2024 * 58.22M Net cash position 2025 * - EV / Sales 2025 * 1.84 x
P/E ratio 2024 *
-1.77 x
P/E ratio 2025 *
-1.75 x
Employees 117
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Syros Pharmaceuticals, Inc.

1 day-6.56%
1 week-7.74%
Current month-19.56%
1 month-20.44%
3 months-20.11%
6 months+46.73%
Current year-25.03%
More quotes
1 week
5.44
Extreme 5.44
6.49
1 month
5.44
Extreme 5.44
7.90
Current year
5.44
Extreme 5.44
8.17
1 year
2.09
Extreme 2.0902
8.17
3 years
2.09
Extreme 2.0902
82.00
5 years
2.09
Extreme 2.0902
156.50
10 years
2.09
Extreme 2.0902
243.75
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 21-09-26
Director of Finance/CFO 56 21-10-11
Chief Tech/Sci/R&D Officer 61 15-12-06
Members of the board TitleAgeSince
Director/Board Member 56 17-06-11
Director/Board Member 71 22-09-15
Director/Board Member 70 15-10-18
More insiders
Date Price Change Volume
24-03-27 5.84 -6.56% 431,796
24-03-26 6.25 -2.34% 108,950
24-03-25 6.4 +2.07% 156,038
24-03-22 6.27 -1.10% 62,303
24-03-21 6.34 +0.16% 107,080

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. Its lead product candidates include Tamibarotene and SY-2101. Its Tamibarotene, is a selective retinoic acid receptor alpha (RAR?), agonist RARA-positive patients with higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML). Its SY-2101, is an oral form of arsenic trioxide (ATO) being developed for the treatment of acute promyelocytic leukemia (APL). The Company's product candidate also includes SY-5609, which is a selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7) which is being developed for patients with select solid tumors and in combination with gemcitabine and with gemcitabine plus nab-paclitaxel in patients with metastatic pancreatic cancer. It is also focused on the development for the treatment of multiple preclinical programs in oncology.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.84 USD
Average target price
19.25 USD
Spread / Average Target
+229.62%
Consensus
  1. Stock
  2. Equities
  3. Stock Syros Pharmaceuticals, Inc. - Nasdaq